Talphera, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $57.6M
- Price
- $1.11
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.31%
- Volume
- 115.8K
About
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
Quick stats
Shares outstanding51.9M
Computed float46.4M
Float / shares89.5%
Cash runway (months)12.5
Key info
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001427925
Websitehttps://talphera.com
AI Summary
AI-generated1/9
minorneutralother
Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Talphera management will present at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026 at 4:30pm ET in New York.
CEO Vince Angotti and Chief Medical Officer Shakil Aslam will lead a fireside chat and one-on-one meetings, with a webcast replay available for 90 days after the event.
The release contains no new clinical, regulatory, or financial data; Talphera's lead candidate Niyad remains under an investigational device exemption with FDA Breakthrough Device Designation, studied as an anticoagulant for the extracorporeal circuit.